News

Under the terms of the agreement, BioInvent will apply its antibody discovery technology to generate and develop monoclonal antibody candidates. The collaboration will initially focus on the development

The warning is also of particular significance to patients with surgical mesh implants, and also hospitals and surgical centers, operating room medical professionals and staff, and purchasing and

The four-year agreement includes some minimum purchases and may be extended through mutual consent. Stephen Beatty, president and CEO of Helix BioMedix, said: “RubyDerm Bio gives the Company

As per the agreement, Torrent will provide AstraZeneca with a portfolio of generic medicines for which the Indian group already has licenses in a range of countries, starting

All patients enrolled in the trial used Gleevec for a minimum of one year and still had cancer cells present. The study was conducted by researchers at the

The lurasidone NDA includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients. The efficacy and safety of lurasidone were evaluated in five six-week,

Brentuximab vedotin, an ADC that utilises the vcMMAE drug-linker unit, is in a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for relapsed

The company said that Preflucel is made using its Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International

Orphan drug designation provides a seven-year term of market exclusivity for IPF upon final FDA approval. Orphan drug designation would position NeoPharm to be able to take advantage